🧾 What This Document Is

This is a transcript from Boston Scientific's Q1 2026 earnings call, filed with the SEC as a Form 425. This filing type is used when companies want to share information about "business combinations"—in this case, their planned acquisition of Penumbra, Inc. Think of it as a public update on the deal, shared during their regular financial results call.

🏢 What The Company Does

👉 In simple terms, Boston Scientific is a global medical technology giant. They make devices that treat a wide range of conditions, including heart rhythm disorders, cancer, and digestive diseases. The company on the other side of this deal, Penumbra, specializes in devices for removing blood clots in strokes and other vessels.

💰 Financial Highlights (Boston Scientific)

The call focused on Boston Scientific's overall performance. Key metrics they highlighted:

• Organic Revenue Growth: The company reported its growth on an "organic" basis, which means they remove the effects of currency swings and recent acquisitions to show how the core business is performing.
• Profitability: They presented both GAAP (standard accounting) and non-GAAP (adjusted) results, with reconciliations available on their investor website.

👉 The big takeaway: The company's financial foundation is strong enough to support major strategic moves, like buying Penumbra.

🤝 The Penumbra Deal

This is the main event. Here are the critical details of the proposed acquisition:

• Status: The deal is expected to close in the second half of 2026.
• Key Milestone: A critical Penumbra shareholder vote is scheduled for May 6, 2026. Boston Scientific's CEO, Mike Mahoney, expressed confidence it will be approved.
• Closing Conditions: Besides the shareholder vote, the deal still needs "customary regulatory clearances" to be finalized.
• Deal Structure: The guidance for Boston Scientific's business excludes Penumbra, meaning they are keeping their forecasts separate until the deal closes.

👉 Why it matters: This shows the deal is progressing through the necessary legal and shareholder steps, but it's not a done deal yet.

🚀 Strategic Vision & Business Momentum

Boston Scientific's leadership is particularly excited about how Penumbra fits into their future.

• "Interventional Oncology": This is a high-growth business area for Boston Scientific, which grew in the "mid-teens" recently. Adding Penumbra's portfolio here would make this segment a "very unique, powerful growth driver."
• Integration Plan: CEO Mike Mahoney stated they plan to run Penumbra as its own business unit, keeping its leadership, sales team, and R&D pipeline intact—similar to how they've successfully integrated other companies.

👉 The strategy is to enhance, not dismantle, what has made Penumbra successful.

💼 Capital Allocation & Other Moves

The company outlined its spending priorities:

1. Strategic Acquisitions: Buying companies that fit neatly into their existing business (like the recent purchase of Valencia Technologies for their Urology business).
2. Share Repurchases: Buying back their own stock.

• Penumbra's Role: The Penumbra acquisition is their major strategic bet, sitting at the top of their priority list.
• Stock Price Question: An analyst asked if Boston Scientific would be willing to add more cash to the Penumbra deal if their own stock price dropped, affecting the deal's value. The CEO reaffirmed their commitment to the deal's original valuation.

🔮 What's Next

• May 6, 2026: Penumbra's shareholder vote on the acquisition.
• H2 2026: Target closing window for the deal, pending approvals.
• For Investors: More attention will shift from their WATCHMAN heart device to their Interventional Oncology business, especially if the Penumbra deal adds fuel to that segment.

⚖️ Big Picture

👍 Strengths:

• Clear strategic vision to fill portfolio gaps with high-quality acquisitions.
• Confidence in Penumbra's team and technology, planning to preserve its operating independence.
• Strong enough financial position to prioritize large M&A.

⚠️ Risks:

• Deal Completion Risk: The acquisition is still subject to a shareholder vote and regulatory approval.
• Integration Risk: Successfully merging Penumbra's culture and operations is never guaranteed.
• Market Reaction: Fluctuations in Boston Scientific's stock price could create financial complexities.

🧠 The Analogy

Think of Boston Scientific as a top chef assembling the ultimate tasting menu. They already have excellent courses (heart, urology devices). Penumbra is a prized, specialized ingredient (stroke care) they need to complete the experience. The earnings call was like the chef telling diners (investors), "We've secured the ingredient from the supplier, and once the final paperwork is signed (shareholder vote), we'll be able to present the full, magnificent menu."

🧩 Final Takeaway

Boston Scientific is on a clear path to acquire Penumbra, viewing it as a transformative growth engine. The key date to watch is May 6, 2026, when Penumbra's shareholders will vote on the deal, moving it one step closer to becoming a reality in the second half of the year.